

Serum protein biomarkers for degenerative cervical myelopathy: a prospective pilot study

Aditya Vedantam, MD¹, Mahmudur Rahman, MS, Sakib Salam, MS¹, Anjishnu Banerjee, Ph.D.², Kajana Satkunendrarajah, Ph.D.¹, Matthew D. Budde, Ph.D.¹, & Timothy B. Meier, Ph.D.¹

¹Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI

²Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI

Corresponding Author:

Aditya Vedantam, MD

Associate Professor of Neurosurgery

Medical College of Wisconsin

avedantam@mcw.edu

CONFIDENTIAL

35 **Abstract**

36

37 **Introduction**

38 Diagnosis of degenerative cervical myelopathy (DCM) is primarily based on clinical evaluation and evidence
39 of cervical spinal cord compression on conventional MRI. However, delays in diagnosis are common in
40 DCM and there is a need for additional objective assessments of spinal cord structure and function. Serum
41 proteins are increasingly being used as biomarkers for neurological disorders and are promising targets for
42 biomarker discovery in DCM. The objective of this study was to profile serum protein biomarkers in DCM
43 and determine if serum proteins can aid diagnosis and prognosis in DCM.

44

45 **Methods**

46 Patients with a clinical diagnosis of DCM and scheduled to undergo decompressive surgery were
47 prospectively enrolled from July 2022 to August 2023. Serum was obtained prior to surgery and at 3 months
48 after surgery. Serum neuronal and inflammatory proteins were quantified using ultrasensitive single-
49 molecular array technology. Serum biomarker concentrations were compared between DCM patients and
50 age- and sex-matched healthy controls. Robust logistic regression was used to determine the panel of serum
51 biomarkers that best differentiated DCM and controls. Serum biomarkers were also related to pre- and post-
52 surgical functional measurements using linear regression.

53

54 **Results**

55 Twenty DCM patients (median age 70 years, 10 females) and 10 healthy controls (median age 65 years, 5
56 females) were enrolled. Pre-surgical NfL (30.2 vs 11.2 pg/ml, $p=0.01$) and IL-6 (2.9 vs 1.2, $p=0.003$) was
57 significantly higher in DCM patients compared to controls. Pre-surgical NfL, IL-6 and BDNF best
58 differentiated DCM and controls ($p<0.001$). At 3 months after surgery, significant increase in serum BDNF
59 ($p=0.001$), AB-42 ($p=0.042$) and TNFa ($p=0.007$) were noted. Pre-surgical serum NfL was significantly
60 associated improvement in pinch strength after surgery ($p<0.05$). Inflammatory biomarkers were linked to
61 improvement in the neck pain-related disability and upper limb function assessed by the QuickDASH.

62

63 **Conclusion**

64 A pre-surgical serum panel of NfL, IL-6 and BDNF may aid in the diagnosis of DCM. Serum NfL is
65 elevated in DCM and is associated with improvement in post-surgical objective measures of upper limb
66 function. Pre-surgical serum neuronal and inflammatory biomarkers predict early post-surgical functional
67 outcomes in DCM.

68

69 **Introduction**

70 Degenerative cervical myelopathy (DCM) is the most common cause of non-traumatic spinal cord injury
71 worldwide¹ with an estimated prevalence of 605 per million in North America.² The pathophysiology of
72 DCM is characterized by chronic spinal cord compression, spinal cord ischemia, neuroinflammation
73 ultimately leading to axonal injury and demyelination.² Many of the early symptoms of DCM are subtle,
74 difficult to confirm on clinical examination, and may be confounded by co-morbid conditions. This can lead
75 to a delay in diagnosis and surgical intervention, which contributes to poorer recovery of neurological
76 function. Surgical decompression of the cervical spinal cord is the primary treatment for DCM and surgical
77 decision-making is primarily based on the clinical examination findings and evidence of cervical spinal cord
78 compression on conventional MRI. The degree of spinal cord compression on conventional MRI, however,
79 correlates poorly with neurological dysfunction in myelopathy,^{3,4} yet this remains a major driver behind the
80 decision to offer surgery.⁵ To better identify patients who will benefit from surgery, there is a need for
81 additional objective assessments of spinal cord structure and function.

82

83 Serum proteins are promising targets for biomarker discovery in DCM due to ease of obtaining
84 biospecimens, potential for repeated sampling and objective quantification. Serum biomarkers such as NfL⁶
85 and GFAP⁷ are elevated in in spinal cord pathologies such as traumatic spinal cord injury,⁸ multiple
86 sclerosis,⁹ amyotrophic lateral sclerosis¹⁰ and transverse myelitis,¹¹ highlighting a close relationship between
87 serum biomarkers and spinal cord damage. Since DCM is a form of chronic spinal cord injury, which
88 includes spinal cord ischemia and neuroinflammation,¹² it is expected that serum biomarkers will reflect
89 ongoing spinal cord damage as well as recovery of neurological function after surgery.

90

91 The aim of this pilot study was to profile serum biomarkers for DCM before and after surgical
92 decompression and determine whether these biomarkers are associated with pre-surgical and early post-
93 surgical function.

94

95 **Methods**

96 Patients with a clinical diagnosis of DCM and scheduled to undergo decompressive surgery were enrolled
97 prospectively from July 2022 to August 2023. DCM patients (aged 18-90 years) with one or more signs of
98 symptoms of cervical myelopathy in addition to evidence of cervical spinal cord compression on MRI were
99 included. We excluded patients with trauma, syringomyelia, cord hemorrhage, tumor, pregnancy and other
100 neurological or muscular diseases that could explain their symptoms as well as those with a history of prior
101 cervical spine surgery. Age- and sex-matched healthy controls with no history of neck symptoms or

102 neurological or muscular diseases were also enrolled. Institutional review board approval was obtained, and
103 all participants provided written informed consent.

104

105 *Serum sampling*

106 Blood was drawn via venipuncture for both DCM patients and controls. For DCM patients, blood was drawn
107 before surgery and at 3 months after surgery. Samples were allowed to clot upright 30-60 minutes prior to
108 centrifugation at 1300-1500x g for 10 minutes in a swing bucket centrifuge at room temperature, after which
109 the serum was collected. Samples were stored at -80 C in 0.5ml aliquots prior to biomarker quantification.

110

111 *Biomarker Quantification*

112 Biomarker concentrations were quantified by Quanterix (Billerica, MA) using manufacturer protocols and
113 reagents. This proprietary ultrasensitive single-molecular array (Simoa) technology has previously been used
114 in prior biomarker studies.⁸ For the purposes of this study, we quantified the concentrations of BDNF
115 (product code: 102039), NF-L, GFAP, AB40, AB42 (N4PE kit, product code: 103670), and Tau (product
116 code: 105168). Inflammatory biomarkers were quantified using the Simoa CorPlex Human Cytokine Panel
117 for IFN-gamma, IL-1beta, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-22 and TNFa. All testing was
118 performed in duplicate and the average concentration with dilution correction was used for statistical
119 analysis.

120

121 *Functional Testing*

122 All DCM participants underwent pre-surgical and post-surgical (at 3 months after surgery) functional testing.
123 Functional measures included the modified Japanese Orthopedic Association scale (mJOA) which is a
124 myelopathy-specific symptom survey. Other symptom surveys included the Neck Disability Index (NDI),
125 which measures how neck pain affects daily living and the QuickDASH, which surveys upper limb
126 dysfunction during activities of daily living. Balance was assessed using the Berg Balance Scale (BBS).
127 Quality of life was quantified using the Short Form 36 Physical Component Score version 2 (SF36 PCS).
128 Objective measures of upper limb function included handgrip strength (measured using Jamar Plus Hand
129 Dynamometer) and pinch strength (measured using Jamar Digital Pinch Gauge). Handgrip and pinch
130 strength were recorded as the average of three trials for each hand and the mean between right and left hands
131 was used for analysis.

132

133 *Statistical analysis*

134 Biomarker concentrations were compared between DCM and control groups using unpaired t-tests (non-
135 parametric Wilcoxon rank sum tests if either normality or homogeneity of variance was violated); similarly,

136 DCM pre -and post-surgery measures were compared using paired t-tests (non-parametric Wilcoxon signed
137 rank test whenever assumptions of normality or homogeneity of variance violated). For continuous
138 outcomes, linear regression was used to test associations between biomarkers and pre-surgery function or
139 biomarkers and change in function after surgery. Change in function after surgery was calculated as the
140 difference in functional score between pre-surgery and post-surgery time points. Robust logistic regression
141 with Huber type regularized estimators¹³ was performed to determine which biomarkers best differentiated
142 DCM and controls. Stepwise methods were used to find the best set of predictor variables for each regression
143 model. Estimates for the area under the ROC curves (AUC, c-statistic) were used to measure diagnostic
144 ability of biomarkers for DCM, with confidence interval being reported for each reported c-statistic.
145 Statistical analysis was performed using R version 4.4.0 and SPSS version 23.

146

147 **Results**

148 Twenty participants with DCM and 10 healthy controls were enrolled. All DCM participants underwent
149 surgery for DCM and had 3 month follow-up. Baseline demographic data are shown in **Table 1**. There were
150 no significant differences in age ($p=0.18$) and sex ($p>0.9$) between DCM participants and controls.

151

152 Serum concentrations of IFN-gamma, IL-1beta, IL-4, IL-5 and IL-12p70 had multiple values (greater than
153 50%) below the lower limit of quantification and were not included in the analysis. For TNFa, eight out of 50
154 samples were below lower limit of quantification and extrapolated lower limit values were used. For one pre-
155 surgical sample, TNFa was below the limit of detection and was removed from the analysis. For one pre-
156 surgical sample, NfL could not be quantified due to technical issues during processing. Pre- and post-surgical
157 functional measures are shown in **Table 2**. Pre-surgical grip and pinch strength were not available for two
158 subjects.

159

160 *Pre-surgical serum biomarkers*

161 Serum NfL (30.2 vs 11.2 pg/ml, $p=0.01$) and IL-6 (2.9 vs 1.2 pg/ml, $p=0.003$) were significantly higher in
162 pre-surgical plasma from DCM participants as compared to healthy controls (**Figure 1**). Serum GFAP (132
163 vs 103 pg/ml, $p=0.22$) was also higher in DCM participants, however, the difference was not statistically
164 significant. No significant difference in concentration of other serum protein biomarkers were noted (**Table**
165 **1**). Using Huber type estimators in a robust logistic regression controlling for age, the serum biomarker panel
166 that best differentiated DCM and healthy controls included NfL, IL-6 and BDNF ($p<0.001$). ROC curves
167 analysis for serum NfL (AUC 0.79, 95% CI 0.62-0.96), IL-6 (AUC 0.84, 95% CI 0.65-1.00) and BDNF
168 (AUC 0.35, 95% CI 0.14-0.57) are shown in **Figure 2**. The combined panel of NfL, IL-6, and BDNF
169 demonstrated an AUC = 0.83, 95% CI 0.68-0.98.

170

171 *Association between pre-surgical serum biomarkers and pre-surgical function*

172 No significant associations between pre-surgical biomarkers and mJOA, NDI or QuickDASH were noted
173 (**Table 3**). Pre-surgical serum IL-22 was significantly linked to the pre-surgical balance as measured by the
174 BBS score. Multiple serum biomarkers (GFAP, BDNF, AB40, AB42, IL-6, IL-8, IL-22) were significantly
175 associated with pre-surgical quality of life as measured by SF36 PCS.

176

177 *Change in serum biomarkers at 3 months after surgery for DCM*

178 Statistically significant increases in BDNF ($p=0.001$), AB-42 ($p=0.042$) and TNF α ($p=0.007$) were noted at 3
179 months after surgery (**Figure 3**). Although serum NfL decreased ($p=0.23$) after surgery, the difference was
180 not statistically significant. No significant change was noted in any of the other serum biomarkers after
181 surgery.

182

183 *Association between pre-surgical biomarkers and change in function after surgery*

184 Pre-surgical serum AB-40 ($p=0.02$) was significantly associated with improvement in mJOA at 3 months
185 after surgery. Multiple serum biomarkers predicted improvement in NDI and QuickDASH at 3 months after
186 surgery (**Table 4**). Pre-surgical IL-10 predicted improvements in upper limb function as measured by
187 QuickDASH and quality of life measured by SF36 PCS. Pre-surgical NfL was significantly ($p=0.03$)
188 associated with improvement in mean pinch strength at follow-up.

189

190 **Discussion**

191 Objective measures of spinal cord structure and function are needed to improve surgical selection for DCM
192 and serum biomarkers show promise in fulfilling this clinical need. This pilot study evaluated a panel of
193 serum biomarkers for diagnosis and prognosis in DCM. Serum NfL, IL-6 and BDNF were associated with a
194 diagnosis of DCM. Serum NfL was strongly associated with baseline and follow-up quantitative hand
195 function. Serum BDNF, AB-42 and TNF α showed significant increases in concentration at 3 months after
196 surgery. Pre-surgical inflammatory and neuronal serum biomarkers were linked to improvements in post-
197 surgical symptom scores.

198

199 Compared to healthy controls, DCM was associated with higher serum NfL and IL-6 concentrations. NfL is
200 a marker of cytoskeletal neuronal injury, and prior studies have shown the pre-surgical CSF levels of NfL are
201 elevated in DCM¹⁴ and can predict post-surgical outcome.¹⁵ Serum NfL levels show strong linear
202 correlations to levels in spinal CSF indicating a spinal cord source for the NfL and potential for biomarker
203 detection using blood samples after spinal cord injury.⁸ Elevated levels of serum NfL have been observed in

204 multiple sclerosis,¹⁶ amyotrophic lateral sclerosis¹⁰ as well as after acute spinal cord injury⁸ highlighting its
205 role as a biomarker of active spinal cord damage. While elevated serum NfL levels are not specific to DCM,
206 NfL levels can support the diagnosis of DCM in patients with high clinical suspicion. NfL levels did
207 decrease at 3 months after surgery (29.1% decrease in median NfL levels), but the difference was not
208 statistically significant. Studies in multiple sclerosis show a greater than 35% reduction in NfL levels at 6
209 months after starting treatment and further reduction at 24 months⁹ suggesting that NfL levels may continue
210 to decrease at longer follow-up after surgery for DCM. IL-6 is produced by immune cells in the peripheral
211 blood as well as by neurons in the CNS, and is known to be elevated in Parkinson's disease and multiple
212 sclerosis.¹⁷ It is a pleiotropic cytokine with pro-inflammatory and neuro-regenerative effects with evidence
213 for promoting recovery after experimental spinal cord injury.¹⁸ In DCM, elevated levels of IL-6 have been
214 measured in the CSF,¹⁹ and serum IL-6 has been shown to be elevated in patients with degenerative disk
215 disease.²⁰ At 3 months after surgery, IL-6 concentrations remained persistently higher than controls (p=0.01).
216 Together, elevated levels of serum IL-6 prior to surgery may be linked to active neurodegeneration as well as
217 disk degeneration, which are seen commonly in DCM. The panel of serum biomarkers (NfL, IL-6 and
218 BDNF) best differentiated DCM and controls. BDNF plays a role in brain plasticity, which is seen in DCM
219 prior to surgery²¹ due to the chronic spinal cord compression. Val66Met mutations in the BDNF gene have
220 been associated with poorer baseline function in DCM suggesting a role for BDNF in the pathophysiology of
221 the disease.²² Together, this panel of serum biomarkers captures structural neuronal injury, inflammation and
222 neuronal plasticity, which play a role in the pathophysiology of DCM.

223
224 There was a significant increase in serum neuronal (BDNF, AB-42) and inflammatory biomarkers (TNF α) at
225 3 months after surgery when comparing pre- and post-surgical samples in DCM patients. The increase in
226 BDNF could be explained by its role in plasticity and neurological recovery, as shown in experimental spinal
227 cord injury.²³ In this study we noted a small but significant increase in AB-42 concentration after surgery.
228 Amyloid breakdown proteins such as AB-42 are lower in CSF in DCM patients compared to controls.¹⁴ An
229 increase in blood²⁴ and CSF AB-42 levels²⁵ is seen after major surgery indicating an association between
230 surgical intervention and elevated plasma AB-42 concentration so it is unclear if our result is related to the
231 surgical intervention or neurological recovery. While TNF α concentrations in CSF in cervical myelopathy
232 are low,^{19,26} prior studies have shown that TNF α contributes to neuroinflammation and blood spinal cord
233 barrier disruption that can persist in the chronic stages of DCM.²⁷ However, serum TNF α also increases after
234 major surgery,²⁸ which may explain the findings in this study.

235
236 Correlations between pre surgical biomarkers and baseline neurological function as measured by standard
237 symptoms scores were not robust. These findings are not entirely unexpected given the subjective nature of

238 these symptom scores as well as their limited granularity and range.²⁹⁻³¹ Prior studies have shown that serum
239 biomarkers are linked to more objective functional measures after spinal cord injury such as the ASIA
240 grade.⁸ Higher pre-surgical NfL was associated with greater mean pre-surgical hand grip strength but the
241 relationship was not statistically significant ($p=0.09$). Multiple neuronal and inflammatory biomarkers were
242 linked to pre-surgical quality of life (SF36 PCS), which is not a disease-specific survey but could represent
243 the effect of pain and disability. Inflammatory markers could be elevated due to pre-surgical pain, which is
244 often present in these patients due to associated osteoarthritis of the cervical spine.

245

246 Several pre-surgical biomarkers were associated with early post-surgical function outcomes in this study.
247 Pre-surgical serum NfL was positively associated with improvements in pinch strength, demonstrating the
248 link between neuronal injury and objective measures of neurological function. Objective markers of hand
249 function such as pinch strength are increasingly being used for DCM and show robust improvements after
250 surgery.³² Serum NfL is elevated rapidly after acute spinal cord injury⁸ and CSF NfL is higher in patients
251 with shorter duration of symptoms.¹⁴ These findings suggest that NfL is associated with more recent axonal
252 injury. Higher pre-surgical NfL levels in serum and CSF are linked to improved outcomes in DCM.¹⁴ Higher
253 presurgical serum AB40 was the only biomarker to be significantly associated with improvement in mJOA
254 scores at 3 months. AB40 levels are elevated acutely after CNS injury and decrease in the chronic phase,
255 with higher acute CSF AB40 levels linked to neurological improvement in traumatic brain injury.³³ Higher
256 AB40 levels prior to surgery may indicate more acute injury with a higher potential for neurological
257 recovery. Improvement in NDI was associated with several pre-surgical neuronal as well as inflammatory
258 biomarkers indicating that changes in neck pain-related disability after surgery are linked to complex multi-
259 system biological processes including inflammation. We found a similar finding with improvements in
260 QuickDASH, which is also a subjective symptom score that assess the impact of upper limb pain and
261 disability.

262

263 This pilot study is limited by a small sample size as well as short term outcome data. We chose a 3-month
264 time-point after surgery for both functional measurements as well as blood biomarker testing since the
265 maximum rate of improvement of neurological function for the majority of DCM patients occurs in the first
266 3 months after surgery.³⁴ However, we acknowledge that patients with severe myelopathy do have potential
267 to show continued improvement from 3 to 12 months after surgery.³⁵ Although we excluded DCM
268 participants with neurological conditions such as multiple sclerosis or prior ischemic strokes, other co-
269 morbidities may impact serum biomarker levels.

270

271 The strength of this study is the prospective homogenous cohort of DCM participants with pre- and post-
272 surgical serum biomarker quantification. While the majority of prior studies have focused on CSF
273 biomarkers for DCM,^{14,15} the results of this study highlight the utility of serum biomarkers, which show
274 greater potential for clinical adoption given ease of sampling. Serum biomarkers (NfL, IL-6 and BDNF) can
275 potentially aid in diagnosis of mild DCM, where patients may not demonstrate physical signs of myelopathy.
276 The inclusion of pre- and post-surgical functional measurements enabled identification of clinical correlates
277 of serum biomarkers in DCM. Serum biomarkers show potential for prognostication of function after surgery
278 in DCM, which is a critical need in the field. Since over 30% of DCM patients do not achieve the minimum
279 clinically important difference for function after surgery,^{36,37} improved prognostication will improve surgical
280 counseling and selection of patients for surgery. We intend to validate the results of this study using a larger
281 sample size as well as extending the duration of follow up after surgery.

282

283 **Conclusion**

284 Serum proteins are promising objective diagnostic and prognostic biomarkers for DCM. If validated, these
285 results suggest that serum biomarkers can help diagnose and identify DCM patients who will respond best to
286 surgical intervention.

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305 **References**

- 306 1. New PW, Cripps RA, Bonne Lee B. Global maps of non-traumatic spinal cord injury epidemiology:
307 towards a living data repository. *Spinal Cord*. 2014;52:97–109.
- 308 2. Nouri A, Tetreault L, Singh A, Karadimas SK, Fehlings MG. Degenerative Cervical Myelopathy:
309 Epidemiology, Genetics, and Pathogenesis. *Spine*. 2015;40:E675-693.
- 310 3. Rhee JM, Heflin JA, Hamasaki T, Freedman B. Prevalence of physical signs in cervical myelopathy: a
311 prospective, controlled study. *Spine*. 2009;34:890–895.
- 312 4. Nagata K, Yoshimura N, Muraki S, et al. Prevalence of cervical cord compression and its association
313 with physical performance in a population-based cohort in Japan: the Wakayama Spine Study. *Spine*.
314 2012;37:1892–1898.
- 315 5. Hilton B, Tempest-Mitchell J, Davies BM, et al. Cord compression defined by MRI is the driving factor
316 behind the decision to operate in Degenerative Cervical Myelopathy despite poor correlation with
317 disease severity. *PloS One*. 2019;14:e0226020.
- 318 6. Barro C, Chitnis T, Weiner HL. Blood neurofilament light: a critical review of its application to
319 neurologic disease. *Ann Clin Transl Neurol*. 2020;7:2508–2523.
- 320 7. Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and
321 spinal cord disorders. *Nat Rev Neurol*. 2022;18:158–172.
- 322 8. Stukas S, Cooper J, Gill J, et al. Association of CSF and Serum Neurofilament Light and Glial Fibrillary
323 Acidic Protein, Injury Severity, and Outcome in Spinal Cord Injury. *Neurology*. 2023;100:e1221–
324 e1233.
- 325 9. Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease
326 activity and treatment response. *Neurology*. 2019;92:e1007–e1015.
- 327 10. Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential
328 pharmacodynamic biomarkers for ALS. *Neurology*. 2020;95:e59–e69.
- 329 11. Lee HL, Seok JM, Chung YH, et al. Serum neurofilament and glial fibrillary acidic protein in idiopathic
330 and seropositive transverse myelitis. *Mult Scler Relat Disord*. 2023;79:104957.

- 331 12. Fehlings MG, Skaf G. A review of the pathophysiology of cervical spondylotic myelopathy with insights
332 for potential novel mechanisms drawn from traumatic spinal cord injury. *Spine*. 1998;23:2730–2737.
- 333 13. Cantoni E, Ronchetti E. A robust approach for skewed and heavy-tailed outcomes in the analysis of
334 health care expenditures. *J Health Econ*. 2006;25:198–213.
- 335 14. Tsitsopoulos PP, Holmström U, Blennow K, Zetterberg H, Marklund N. Cerebrospinal fluid biomarkers
336 of glial and axonal injury in cervical spondylotic myelopathy. *J Neurosurg Spine*. 2021;34:632–641.
- 337 15. Tsitsopoulos PP, Mondello S, Holmström U, Marklund N. Cerebrospinal fluid biomarkers of white
338 matter injury and astrogliosis are associated with the severity and surgical outcome of degenerative
339 cervical spondylotic myelopathy. *Spine J Off J North Am Spine Soc*. 2022;22:1848–1856.
- 340 16. Kapoor R, Smith KE, Allegretta M, et al. Serum neurofilament light as a biomarker in progressive
341 multiple sclerosis. *Neurology*. 2020;95:436–444.
- 342 17. Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. *Biochim*
343 *Biophys Acta*. 2016;1863:1218–1227.
- 344 18. Yang P, Wen H, Ou S, Cui J, Fan D. IL-6 promotes regeneration and functional recovery after cortical
345 spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse
346 formation. *Exp Neurol*. 2012;236:19–27.
- 347 19. Nagashima H, Morio Y, Yamane K, Nanjo Y, Teshima R. Tumor necrosis factor-alpha, interleukin-
348 1beta, and interleukin-6 in the cerebrospinal fluid of patients with cervical myelopathy and lumbar
349 radiculopathy. *Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res*
350 *Soc*. 2009;18:1946–1950.
- 351 20. Deng X, Zhao F, Kang B, Zhang X. Elevated interleukin-6 expression levels are associated with
352 intervertebral disc degeneration. *Exp Ther Med*. Spandidos Publications; 2016;11:1425–1432.
- 353 21. Cronin AE, Detombe SA, Duggal CA, Duggal N, Bartha R. Spinal cord compression is associated with
354 brain plasticity in degenerative cervical myelopathy. *Brain Commun*. 2021;3:fcab131.
- 355 22. Abode-Iyamah KO, Stoner KE, Grossbach AJ, et al. Effects of brain derived neurotrophic factor
356 Val66Met polymorphism in patients with cervical spondylotic myelopathy. *J Clin Neurosci Off J*
357 *Neurosurg Soc Australas*. 2016;24:117–121.

- 358 23. Weishaupt N, Blesch A, Fouad K. BDNF: the career of a multifaceted neurotrophin in spinal cord injury.
359 *Exp Neurol.* 2012;238:254–264.
- 360 24. Požgain Z, Dulić G, Kondža G, et al. Is postoperative cognitive decline after cardiac surgery associated
361 with plasma beta amyloid 1-42 levels? *J Cardiothorac Surg.* 2022;17:6.
- 362 25. Danielson M, Wiklund A, Granath F, et al. Association between cerebrospinal fluid biomarkers of
363 neuronal injury or amyloidosis and cognitive decline after major surgery. *Br J Anaesth.* 2021;126:467–
364 476.
- 365 26. Ito K, Matsuyama Y, Yukawa Y, Kato F, Ishiguro N. Analysis of interleukin-8, interleukin-10, and
366 tumor necrosis factor-alpha in the cerebrospinal fluid of patients with cervical spondylotic myelopathy.
367 *J Spinal Disord Tech.* 2008;21:145–147.
- 368 27. Karadimas SK, Gatzounis G, Fehlings MG. Pathobiology of cervical spondylotic myelopathy. *Eur Spine*
369 *J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc.* 2015;24 Suppl 2:132–
370 138.
- 371 28. Baxevanis CN, Papilas K, Dedoussis GV, Pavlis T, Papamichail M. Abnormal cytokine serum levels
372 correlate with impaired cellular immune responses after surgery. *Clin Immunol Immunopathol.*
373 1994;71:82–88.
- 374 29. Kopjar B, Tetreault L, Kalsi-Ryan S, Fehlings M. Psychometric properties of the modified Japanese
375 Orthopaedic Association scale in patients with cervical spondylotic myelopathy. *Spine.* 2015;40:E23-
376 28.
- 377 30. Martin AR, Jentzsch T, Wilson JRF, et al. Inter-rater Reliability of the Modified Japanese Orthopedic
378 Association Score in Degenerative Cervical Myelopathy: A Cross-sectional Study. *Spine.*
379 2021;46:1063–1069.
- 380 31. Kalsi-Ryan S, Singh A, Massicotte EM, et al. Ancillary outcome measures for assessment of individuals
381 with cervical spondylotic myelopathy. *Spine.* 2013;38:S111-122.
- 382 32. Cole TS, Almefty KK, Godzik J, et al. Functional improvement in hand strength and dexterity after
383 surgical treatment of cervical spondylotic myelopathy: a prospective quantitative study. *J Neurosurg*
384 *Spine.* Epub 2020 Feb 7.:1–7.

- 385 33. Mondello S, Buki A, Barzo P, et al. CSF and plasma amyloid- β temporal profiles and relationships with
386 neurological status and mortality after severe traumatic brain injury. *Sci Rep*. 2014;4:6446.
- 387 34. Berlin C, Marino AC, Mummaneni PV, et al. Determining the time frame of maximum clinical
388 improvement in surgical decompression for cervical spondylotic myelopathy when stratified by
389 preoperative myelopathy severity: a cervical Quality Outcomes Database study. *J Neurosurg Spine*.
390 Epub 2022 Jun 17.:1–9.
- 391 35. Khan I, Archer KR, Wanner JP, et al. Trajectory of Improvement in Myelopathic Symptoms From 3 to
392 12 Months Following Surgery for Degenerative Cervical Myelopathy. *Neurosurgery*. 2020;86:763–768.
- 393 36. Tetreault L, Wilson JR, Kotter MRN, et al. Predicting the minimum clinically important difference in
394 patients undergoing surgery for the treatment of degenerative cervical myelopathy. *Neurosurg Focus*.
395 2016;40:E14.
- 396 37. Evaniew N, Cadotte DW, Dea N, et al. Clinical predictors of achieving the minimal clinically important
397 difference after surgery for cervical spondylotic myelopathy: an external validation study from the
398 Canadian Spine Outcomes and Research Network. *J Neurosurg Spine*. Epub 2020 Apr 10.:1–9.
- 399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415

416 **Figure Legends**

417

418 **Figure 1.** Violin plots comparing serum biomarkers for DCM and healthy controls.

419

420 **Figure 2.** ROC curve showing diagnostic accuracy for pre-surgical serum biomarkers for DCM

421

422 **Figure 3.** Violin plots showing serum biomarkers pre-surgery and post-surgery for 20 DCM patients.

423 Outlying data from post-surgical IL-10 concentration (11.5 pg/ml) and TNFa concentration (147.7 pg/ml)

424 from one sample are not plotted

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

CONFIDENTIAL

450 **Tables**

451

452 **Table 1.** Demographic and biomarker data for DCM patients and controls.

453

	DCM (n=20)	Controls (n=10)	P-value
Age in years (min-max)	70 (37-78)	65 (51-76)	0.18
Sex (M/F)	10/10	5/5	>0.9
NfL	30.2 (7.2-62)	11.2 (10-22.5)	0.01*
GFAP	132 (44.8-407)	103 (75.4-223)	0.21
BDNF	18729 (2206-35055)	22969.5 (6900-38084)	0.16
Tau	0.23 (0.1-0.7)	0.25 (0.2-0.5)	0.52
AB40	64.9 (0-117)	67.8 (35.3-100)	0.86
AB42	4.6 (0-7.7)	4.9 (3.1-7.2)	0.69
IL-6	2.9 (1-8.4)	1.2 (0.5-7.2)	0.003*
IL-8	19.5 (7.9-43.8)	17 (9.8-19.6)	0.26
IL-10	0.5 (0.2-2.8)	0.5 (0.1-2.4)	0.59
IL-22	0.8 (0.2-3.7)	0.5 (0.2-3.6)	0.32
TNFa	0.5 (0-1.9)	0.7 (0.4-1)	0.18

454 All biomarkers concentrations in median (minimum - maximum) pg/ml

455 *p<0.05

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

CONFIDENTIAL

484
485
486
487

Table 2. Pre- and post-surgical functional measures for 20 DCM participants

	Pre-surgery	Post-surgery at 3 months	P-value
mJOA	14 (11-17)	16 (11-18)	0.06
NDI	28±17.2	19.6± 15.9	0.015*
QuickDASH	40.8± 17.3	27.4± 17.8	0.001*
BBS	52 (6-56)	54 (17-56)	0.06
SF-36 PCS	36.5± 7.8	39.9± 9.3	0.042*
Hand grip strength			
-Right	66.2 (37.2-152)	83.5 (53.5-172.3)	0.001*
-Left	79.1± 28.5	87.2± 26.6	0.004*
Pinch strength			
-Right	9.8± 3.9	10.8± 5.4	0.42
-Left	10.5± 4.6	11.4±4.8	0.44

488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520

^Normal data is represented as means ± standard deviation and data not normally distributed are represented as median (minimum-maximum)

*p<0.05

CONFIDENTIAL

521
522
523
524
525

Table 3. Significant associations between pre-surgical serum biomarker concentrations and pre-surgical function

Functional measure	Pre-surgical serum Biomarker	Unstandardized co-efficient B (95% CI)	Standard Error	P-value
Pre-surgical functional measure				
mJOA	None			
NDI	None			
QuickDASH	None			
BBS	IL-22	-13.3 (-23.6, -2.9)	4.4	0.02
SF36 PCS	GFAP	-0.05 (-0.09, -0.02)	0.02	0.01
	BDNF	0.001 (0,0.001)	0.0	0.003
	AB40	0.21 (0.03,0.39)	0.08	0.03
	AB42	-3.4 (-6.5, -0.33)	1.3	0.04
	IL-6	4.5 (2.7, 6.2)	0.7	<0.001
	IL-8	-0.6 (-0.8, -0.3)	0.1	0.002
	IL-22	-8.5 (-11.4, -5.5)	1.2	<0.001
Mean hand grip strength	None			
Mean pinch strength	None			

526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550

551
552
553
554
555
556

Table 4. Significant associations between pre-surgical serum biomarker concentrations and change in function at 3 months after surgery

Functional measure	Pre-surgical serum Biomarker	Unstandardized co-efficient B (95% CI)	Standard Error	P-value
Change in functional measures				
mJOA	AB40	-0.18 (-0.3,-0.03)	0.06	0.02
NDI	NfL	0.4 (0.01,0.8)	0.2	0.046
	GFAP	-0.1 (-0.2,-0.001)	0.04	0.049
	BDNF	-0.001 (-0.002,0)	0.0	0.014
	IL-6	-8.1 (-12.9,-3.3)	2.0	0.005
	IL-10	17.5 (5.7,29.2)	4.9	0.01
	IL-22	14.3 (6.0-22.5)	3.5	0.005
	TNFa	24.8 (8.4, 41.3)	6.9	0.009
QuickDASH	BDNF	-0.002 (-0.002,-0.001)	0.0	<0.001
	Tau	-47.4 (-78.9,-15.9)	13.3	0.009
	AB40	0.5 (0.2,0.8)	0.1	0.005
	IL-6	-6.5 (-9.5,-3.5)	1.3	0.001
	IL-8	0.6 (0.1, 1.1)	0.2	0.02
	IL-10	19.3 (11.9,26.6)	2.2	0.005
	IL-22	17.3 (0.9,33.8)	6.9	0.04
BBS	IL-22	9.9 (1.5,18.3)	3.6	0.03
SF36 PCS	IL-10	-7.5 (-14.8,-0.3)	3.1	0.04
Mean hand grip strength	None			
Mean pinch strength	NfL	0.3 (0.04,0.6)	0.1	0.03

557
558





